Konstantinos George Vahtsevanos

Prof. Konstantinos George Vahtsevanos


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
VAVaia-Aikaterini Alexoudi
Vaia-Aikaterini Alexoudi
Eleni GavriilakiEleni Gavriilaki
Eleni Gavriilaki
ACAngeliki Cheva
Angeliki Cheva
ISIoanna Sakellari
Ioanna Sakellari
SPStavroula Papadopoulou
Stavroula Papadopoulou
KVKonstantinos George Vahtsevanos
Konstantinos George Vahtsevanos
A crucial complication after allogeneic hematopoietic cell transplantation (alloHCT), namely, acute graft-versus-host disease (aGVHD), occurs in about 50% of transplant recipients, leading to high morbidity and mortality. Thus far, the diagnosis of GVHD has been mainly established through clinical features and histologic or laboratory evidence of periductal lymphocyte infiltration, fibroplasia, and mixed lymphocytic and plasmocytic inflammation. Intensive research is focused on identifying biomarkers for the early diagnosis, prediction of disease, response to treatment, prognosis, and risk stratification of patients. The serum biomolecules that have been investigated are reported and summarized. Moreover, oral tissue involvement in GVHD is described, and other biomarkers that have been proposed, such as saliva, are analyzed. Future research is highlighted as a necessity in order for these biomarkers to be validated and quantified for use in clinical practice.

23 February 2022 in Cureus
Verified
Journal Article
Open access
DPDimitra Palitzika
Dimitra Palitzika
ITIoannis Tilaveridis
Ioannis Tilaveridis
Maria LavdanitiMaria Lavdaniti
Maria Lavdaniti
KVKonstantinos George Vahtsevanos
Konstantinos George Vahtsevanos
AKAngeliki Kosintzi
Angeliki Kosintzi
KAKonstantinos Antoniades
Konstantinos Antoniades
The project assessed the quality of life in post-operative patients with tongue cancer at three-month intervals in the first year after the operation. A longitudinal prospective cohort study was conducted in the oral and maxillofacial department of a large public general hospital in northern Greece. Fifty-six patients out of a total of 156 with oral cancer were chosen for the study, who completed distinct quality-of-life surveys (EORTC QLQ-C30, and QLQ Head & Neck Module FACT-G). Tumor size correlated negatively with various EORTC QLQ-C30 scores, such as role functioning (p = 0.004) and cognitive functioning (p = 0.007), in the third evaluation. Tumor size correlated positively with subscale problems such as social eating (p = 0.001) and weight loss (p = 0.004) in the QLQ Head & Neck Module. The role functioning subscale (p = 0.003), the pain subscale (p = 0.001), and the speech issues QLQ Head & Neck module subscale (p = 0.003) adversely correlated with cancer stage. Patients who received flap reconstruction significantly differed from those who did not, on the EORTC QLQ-C30 cognitive functioning (U = 139.0, p = 0.006), dyspnea (U = 391.5, p = 0.006), and diarrhea (U = 425.0, p = 0.007) subscales during the third evaluation. Differences were also found in the QLQ-H&N35 subscale of sticky saliva (U = 391.0, p = 0.006). Patients with flap reconstruction did not significantly differ from those with immediate closure after one year. Differences concerned the EORTC QLQ-C30 subscales of cognitive functioning, dyspnea, and diarrhea, and the QLQ Head & Neck Module subscale of sticky saliva on the third assessment. No statistically significant correlations were observed between tumor size and cancer stage in the fourth assessment, but the grade of cancer positively correlated with the EORTC QLQ-C30 subscale of constipation (p = 0.000). Our study suggests that quality of life is impaired in patients with tongue cancer who have undergone surgical interventions, particularly within the first month post-operation. However, quality of life is fully restored one year after the surgical excision. Future studies should explore early interventions to help healthcare providers better treat this unique group of patients.

15 January 2025 in Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
PDF file
Dimitris TatsisDimitris Tatsis
Dimitris Tatsis
AAAsterios Antoniou
Asterios Antoniou
ALAlexandros Louizakis
Alexandros Louizakis
KPKonstantinos Paraskevopoulos
Konstantinos Paraskevopoulos
AKATHANASSIOS KYRGIDIS
ATHANASSIOS KYRGIDIS
KVKonstantinos George Vahtsevanos
Konstantinos George Vahtsevanos

21 November 2024 in DNA
Verified
Journal Article
Open access
PDF file
PPPetros Papadopoulos
Petros Papadopoulos
VZVasileios Zisis
Vasileios Zisis
DADimitrios Andreadis
Dimitrios Andreadis
DPDIMITRIOS PARLITSIS
DIMITRIOS PARLITSIS
ELEirini Louizou
Eirini Louizou
APATHANASIOS POULOPOULOS
ATHANASIOS POULOPOULOS
Background/Objectives: DAPK-1 plays a crucial role among molecules that may be affected by DNA hypermethylation. The aim of this study is to investigate the DNA methylation of DAPK-1 gene in oral potentially malignant disorders (OPMDs) and oral squamous cell carcinoma (OSCC) compared to normal oral epithelium and to evaluate the possible role of methylated DAPK-1 as an indicator of the early onset of malignant transformation of oral potentially malignant disorders. Methods: The paraffin embedded tissue samples were retrieved from the archives of the Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece and St Lukas Hospital of Thessaloniki, Greece during the period of 2014–2019. The tissue samples included 83 OPMDs samples, 39 OSCC samples and 12 samples of normal oral epithelium. The PCR process followed, targeting four different DAPK-1 gene primers. Results: Regarding OSCC, it was found that all 39 OSCCs samples were methylated in DAPK-1 promoter region, whereas only 2 out of 12 normal tissues samples showed DAPK-1 promoter hypermethylation (p < 0.001 Fisher’s exact test). A total of 17 out of 83 OPMDs were DAPK-1 methylated (five erosive oral lichen planus samples, three non-dysplastic oral leukoplakias, eight mildly dysplastic oral leukoplakias and one sample belonging to the group of moderately and severely dysplastic oral leukoplakia). Conclusions: Since epigenetic changes occur early in carcinogenesis and are potentially reversible, they could be used as disease biomarkers for diagnosis, prognosis and prediction, as well as therapeutic targets. DAPK-1 methylation is mostly present in the early stages of dysplasia as well as in all cases of oral cancer.

Verified
Journal Article
Open access
PDF file
IAIOANNIS - SOFIANOS THRASYVOULOS ASTREIDIS
IOANNIS - SOFIANOS THRASYVOULOS ASTREIDIS
IKIlias Kostidis
Ilias Kostidis
AMAndigoni Malousi
Andigoni Malousi
KPKonstantinos Paraskevopoulos
Konstantinos Paraskevopoulos
DADimitrios Andreadis
Dimitrios Andreadis
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis
Tongue squamous cell carcinoma (TSCC) is clinically heterogeneous, and patients with a similar TNM stage can experience markedly different outcomes. We systematically reviewed omics-driven studies to identify prognostic TSCC biomarkers. Although fundamentally prognostic, we discussed their theoretical translational relevance regarding future clinical decisions—such as treatment stratification or surveillance intensity—while strictly framing them as preliminary, hypothesis-generating targets. PubMed, Scopus, Web of Science, and Cochrane were searched for original human studies published between 2014 and 2024 using high-throughput genomic or transcriptomic profiling. Study selection followed referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), data were extracted with a structured workbook, and risk of bias was assessed using QUIPS and PROBAST, with reporting completeness appraised using REMARK. Seventeen studies were included, identifying 85 distinct biomarkers. Across biomarkers supported by multivariable overall survival analyses, higher-risk associations were reported for NELL2, PDE4D, CTTN, HBEGF, and CA9, whereas lower-risk associations were reported for AC139530.1, LINC01711, CCDC96, CYP2J2, and SPAG16. Recurrent biological themes included IL-17 signaling, ECM-receptor interaction, and focal adhesion. CA9 was the only biomarker reported in more than one included study, supporting its prioritization for validation. Although the evidence remains heterogeneous and largely hypothesis-generating, these markers may support the future validation of response-oriented therapeutic stratification in TSCC.

28 February 2022 in Journal of the Korean Association of Oral and Maxillofacial Surgeons
Verified
Journal Article
Open access
PDF file
Dimitris TatsisDimitris Tatsis
Dimitris Tatsis
NKNikolaos Kechagias
Nikolaos Kechagias
ATAntonios Tsekos
Antonios Tsekos
GPGeorgios Petrakis
Georgios Petrakis
KVKonstantinos George Vahtsevanos
Konstantinos George Vahtsevanos
Dimitris Tatsis, Nikolaos Kechagias, Antonios Tsekos, Georgios Petrakis, Konstantinos Vahtsevanos. JKAOMS 2022;48:59-62. https://doi.org/10.5125/jkaoms.2022.48.1.59